Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00063219 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

A Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
13
Study locations

NCT00063219: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00063219 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 48 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00063219, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Lung Neoplasms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
13
Study locations

Study Summary

This non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage of patients with an objective tumor response after treatment with MAC-321. Patients must have been previously treated with a platinum-containing chemotherapy regimen. A total of 96 patients will be enrolled in this trial. Eligible patients will receive MAC-321 intravenously every 3 weeks for up to a total of 6 courses of treatment. All patients will receive MAC-321 at the same dose. MAC-321 is an experimental drug, and is not offered outside of this research trial.

Conditions Studied

Carcinoma, Non-Small Cell Lung Lung Neoplasms

Interventions

  • DRUG MAC-321

Study Locations (13)

Pennsylvania

  • - Philadelphia
  • - Pittsburgh

California

  • - Los Angeles

Kentucky

  • - Lexington

Maryland

  • - Baltimore

Massachusetts

  • - Worcester

Minnesota

  • - Minneapolis

Missouri

  • - St Louis

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 48 participants
Est. Completion 2005-02
Phase Phase 2
Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

What the finished NCT00063219 record still lists

NCT00063219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which MAC-321 is the first listed.

NCT00063219 lists 13 locations in 12 states (Pennsylvania, California, Kentucky).

Frequently Asked Questions

What is clinical trial NCT00063219 about?

NCT00063219 is a clinical study titled "Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy". This non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage of patients with an o...

What is the current status of trial NCT00063219?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. Estimated completion is 2005-02.

What conditions does trial NCT00063219 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Lung Neoplasms.

What interventions are being tested in trial NCT00063219?

The interventions under investigation include: MAC-321 (DRUG).

Who is sponsoring clinical trial NCT00063219?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00063219 being conducted?

This trial has 13 study locations across California, Kentucky, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00063219's enrollment target sits among peer trials

48 96th of 130 higher than 35 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Related registry views

Source: ClinicalTrials.gov NCT00063219, the US trial registry maintained by the National Library of Medicine. NCT00063219 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.